Artificial intelligence for regulatory compliance in pharmaceutical systems enhancing drug safety monitoring, reporting accuracy, and risk management processes

The integration of Artificial Intelligence (AI) into pharmaceutical regulatory compliance is reshaping how organizations manage drug safety, reporting obligations, and risk governance. In a broad context, the pharmaceutical industry faces increasing pressure from stringent regulatory requirements, expanding datasets, and the need for continuous post-market surveillance. Conventional compliance approaches, largely dependent on manual processes, struggle to efficiently handle the scale, complexity, and speed demanded by modern regulatory environments. AI introduces a transformative capability by leveraging advanced techniques such as machine learning, natural language processing, and intelligent data mining to streamline compliance operations. Focusing more specifically, AI-driven tools enhance drug safety monitoring by enabling rapid identification of adverse drug reactions across structured and unstructured data sources. These systems improve reporting precision through automated data capture, coding, and validation processes aligned with global regulatory standards. Additionally, AI strengthens risk management by supporting predictive analytics that anticipate safety issues and guide timely intervention strategies. This facilitates more informed decision-making and continuous benefit–risk evaluation throughout a drug’s lifecycle. Despite these advancements, concerns related to model interpretability, data governance, regulatory trust, and ethical accountability must be addressed to ensure reliable and compliant AI adoption in pharmaceutical systems.